comparemela.com

Latest Breaking News On - ஊதித் பாத்ரா - Page 3 : comparemela.com

ROUNDUP: Merck setzt auf ergänzende Übernahmen - Erstmal keine großen Deals

ROUNDUP: Merck setzt auf ergänzende Übernahmen - Erstmal keine großen Deals
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Can Merck s new boss maintain the drugmaker s winning streak?

F EW COMPANIES have a history as long and interesting as Merck. Founded in 1668 by Friedrich Jacob Merck as a pharmacy in Darmstadt, the world’s oldest apothecary has survived several European wars, two world wars and the Nazi regime. In 1917 America’s government confiscated its American subsidiary under the Trading with the Enemy Act. It has operated as a rival business, based in New Jersey but, confusingly, also named Merck, ever since. Belén Garijo, the no-nonsense 60-year-old Spaniard who will take over as Merck’s chief executive on May 1st, says she is keenly aware of her company’s heritage and its unique ownership structure. Fully 70% of the company is still in the hands of the 13th generation of Mercks (the rest is owned by public investors). And it was at the family’s instigation that Stefan Oschmann, the outgoing

Waters Corporation (WAT) Q4 2020 Earnings Call Transcript

Operator Good morning. Welcome to the Waters Corporation 4th Quarter 2020 Financial Results Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference call begins. This conference call is being recorded. If anyone objects, please disconnect at this it is now my pleasure to turn the call over to Mr. Bryan Brokmeier, Head of Investor Relations. Please go ahead, sir. Bryan Brokmeier Chartered Financial Analyst, Senior Director, Investor Relations Thank you, operator. Good morning everyone and welcome to the Waters Corporation 4th Quarter Earnings Conference Call. Before we begin, I will cover the cautionary language. During the course of this conference call, we will make various forward-looking statements regarding future events or future financial performance of the company. In particular, we will provide guidance regarding possible future results of the company and commentary on potential market and business conditions

Waters 2020 Sustainability Report Highlights Continued Progress of Its Environmental, Social and Governance Initiatives

Waters’ 2020 Sustainability Report Highlights Continued Progress of Its Environmental, Social and Governance Initiatives Waters also named to Newsweek’s “America’s Most Responsible Companies” 2021 List, ranked #19 overall Dec 22, 2020 8:00 AM ET Tweet This:  Article Waters Corporation (NYSE:WAT) today released its 2020 Sustainability Report, highlighting achievements and progress of the company’s sustainable operations, projects and initiatives. Waters’ latest sustainability report covers activities from 2019 and key highlights from 2020. In addition, the report tracks the important progress of Waters 2025 sustainability goals set forth in late 2019. “Our team is demonstrating that through our collective actions we can make meaningful impacts, even during the most challenging periods in our history,” said Dr. Udit Batra, Waters President and CEO. “From investing in STEM education, to reimagining recyclable product packaging, to our COVID-19 Innovation Resp

Waters Corporation Appoints Pearl S Huang to Board of Directors

Share: Waters Corporation (NYSE:WAT) today announced that Dr. Pearl S. Huang, President and CEO of Cygnal Therapeutics and venture partner at Flagship Pioneering, has been appointed as a Director of Waters Corporation, effective January 1, 2021. Dr. Pearl S. Huang (Photo: Business Wire) We are pleased to welcome Pearl to the Waters Board of Directors, said Dr. Flemming Ornskov, Chairman of the Board. Pearl is a distinguished executive with significant scientific expertise in the discovery of biologics, small molecule and nucleic acid-based therapies, as well as a proven track record in drug discovery and the development of clinical trials. We look forward to benefitting from Pearl s perspectives and believe she will add even greater value to Waters distinguished board of scientists and business leaders.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.